Limitations and perspectives Therapeutic approaches targeting cardiac remodeling reversal, including monoclonal antibodies, peptide-based therapies, and AAV vectors, share similar translational challenges with cardiac regeneration strategies, particularly with respect to delivery efficiency and potential off-target effects
Silence, by contrast, required nothing and preserved everything
Every prescription is FDA-approved, supported by extensive trials and manufactured by original pharmaceutical companies
Conclusions By addressing key metabolic dysfunctions, GLP-1RAs have the potential to reduce hepatic steatosis, resolve MASH, and mitigate fibrosis progression
The standard escalation moves from 2.5 mg to 5 mg, then to 7.5 mg, 10 mg, 12.5 mg, and potentially up to 15 mg per week